CONSIDERATIONS TO KNOW ABOUT DEUCRAVACITINIB

There were no clinically substantial differences during the pharmacokinetics of possibly midazolam (CYP3A4 substrate) or repaglinide (CYP2C8 substrate) when employed concomitantly with finerenone. Multiple doses of 40 mg finerenone once-day-to-day experienced no clinically pertinent impact on AUC or Cmax on the BCRP and OATP substrate rosuvastatin.